ES2132227T3 - Procedimiento y composicion para el cuidado de la piel. - Google Patents

Procedimiento y composicion para el cuidado de la piel.

Info

Publication number
ES2132227T3
ES2132227T3 ES93907954T ES93907954T ES2132227T3 ES 2132227 T3 ES2132227 T3 ES 2132227T3 ES 93907954 T ES93907954 T ES 93907954T ES 93907954 T ES93907954 T ES 93907954T ES 2132227 T3 ES2132227 T3 ES 2132227T3
Authority
ES
Spain
Prior art keywords
composition
procedure
skin care
skin
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907954T
Other languages
English (en)
Inventor
Anthony Vincent Rawlings
Ian Richard Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2132227T3 publication Critical patent/ES2132227T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA SU APLICACION TOPICA SOBRE LA PIEL PARA EL ALIVIO O LA PREVENCION DE CONDICIONES DE PIEL SECA Y ESCAMOSA, CASPA O ACNE; LA COMPOSICION COMPRENDE: 1) GLICOSIDASA; Y 2) UNA PROTEASA, LOS COMPONENTES 1) Y 2) ESTAN PRESENTES SIMULTANEAMENTE EN LA COMPOSICION O SE PRESENTAN SEPARADAMENTE CON INDICACION PARA LA APLICACION DEL COMPONENTE 1) ANTES DEL COMPONENTE (2).
ES93907954T 1992-04-02 1993-03-31 Procedimiento y composicion para el cuidado de la piel. Expired - Lifetime ES2132227T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207280A GB9207280D0 (en) 1992-04-02 1992-04-02 Skin care method and composition

Publications (1)

Publication Number Publication Date
ES2132227T3 true ES2132227T3 (es) 1999-08-16

Family

ID=10713365

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907954T Expired - Lifetime ES2132227T3 (es) 1992-04-02 1993-03-31 Procedimiento y composicion para el cuidado de la piel.

Country Status (14)

Country Link
US (1) US5439935A (es)
EP (1) EP0633764B1 (es)
JP (1) JPH07505383A (es)
KR (1) KR950700722A (es)
AT (1) ATE181231T1 (es)
AU (1) AU675426B2 (es)
BR (1) BR9306178A (es)
CA (1) CA2133085A1 (es)
DE (1) DE69325366T2 (es)
ES (1) ES2132227T3 (es)
GB (1) GB9207280D0 (es)
GR (1) GR3031016T3 (es)
WO (1) WO1993019731A1 (es)
ZA (1) ZA932403B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207288D0 (en) * 1992-04-02 1992-05-13 Unilever Plc Cosmetic composition
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
US20060134641A1 (en) * 1992-05-22 2006-06-22 Franklin Richard L Treating viral infections with krill enzymes
US5958406A (en) * 1994-11-22 1999-09-28 Phairson Medical Inc. Acne treatment with multifunctional enzyme
US7947270B2 (en) * 1992-05-22 2011-05-24 Arcimboldo Ab Removing dental plaque with krill enzymes
US5945102A (en) * 1994-11-22 1999-08-31 Phairson Medical Inc. Crustacean and fish derived multifunctional enzyme
IT1270951B (it) * 1993-06-07 1997-05-26 Boehringer Mannheim Italia Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma
AU7656894A (en) * 1993-09-15 1995-04-03 Unilever Plc Skin care method and composition
GB9319103D0 (en) * 1993-09-15 1993-11-03 Unilever Plc Skin care method & composition
FR2721210B1 (fr) * 1994-06-17 1996-08-02 Oreal Composition de nettoyage contenant des grains lipidiques.
FR2725898B1 (fr) * 1994-10-24 1996-12-13 Oreal Produit pour application topique contenant une lipase et un precurseur d'hydroxyacide
FR2729079A1 (fr) * 1995-01-09 1996-07-12 Sederma Sa Nouvelles compositions cosmetiques contenant des ceramides et autres lipides complexes
US6232088B1 (en) 1995-02-08 2001-05-15 Phairson Medical, Inc. Treatment and prevention of immune rejection reactions
FR2732593B1 (fr) * 1995-04-04 1997-05-23 Bieurope Compositions cosmetiques a base d'enzymes proteases ou beta-glucosidases immobilisees pour favoriser l'elimination des cellules superficielles de la peau
DE19600480A1 (de) * 1996-01-09 1997-07-10 Beiersdorf Ag Verwendung von Serin-Proteinasen gegen Akne und entzündete Comedonen
US6407056B1 (en) * 1996-07-12 2002-06-18 Johnson & Johnson Consumer Companies, Inc. Methods for altering hair growth and hair pigmentation by apoptosis in the follicular papillae and compositions therefor
US5776461A (en) * 1996-07-26 1998-07-07 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing phytovitamin D
DE19649096A1 (de) * 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Glycosidasen
DE19649098A1 (de) * 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Proteasen
DE19649097A1 (de) * 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Lipasen
US5811112A (en) * 1997-05-30 1998-09-22 Chesebrough-Pond's Usa Co., Division Of Conopco Inc. Oil-in-water cosmetic emulsions containing a stabilized protease
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
JP2002507426A (ja) 1998-03-26 2002-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー アミノ酸置換を有するセリンプロテアーゼ変異体
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
DE19824073A1 (de) * 1998-05-29 1999-12-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an immobilisierten oder freien Lipasen, die die Viskosität von Hautfett beeinflussen
DE19829789A1 (de) * 1998-07-03 2000-01-05 Beiersdorf Ag Gegen Akne und entzündete Comedonen wirksame Zubereitungen enthaltend Serin-Proteasen und ein oder mehrere Calciumsalze
US6217852B1 (en) 1998-08-15 2001-04-17 Skinnovative Dermatologic Concepts, L.L.C. Personal cleansing compositions having photoprotective agents
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
MXPA02000842A (es) 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
AU6085800A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid substitutions in defined epitope regions
KR20020021397A (ko) 1999-07-22 2002-03-20 데이비드 엠 모이어 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
DE10025720C2 (de) * 2000-05-25 2002-05-29 Walterscheid Gmbh Gkn Antriebsanordnung mit Freilaufkupplung
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002022099A1 (en) * 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic method for treatment of skin and/or hair
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
JP4149378B2 (ja) * 2001-06-29 2008-09-10 株式会社資生堂 複合粉体、及びそれを配合した皮膚外用剤
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030198631A1 (en) * 2002-04-18 2003-10-23 Healthpoint, Ltd. Thermolysin enzymatic wound debrider
US6835385B2 (en) * 2002-06-14 2004-12-28 Carol J. Buck Compositions and methods for softening, thinning and removing hyperkeratotic tissue
DE10237317B4 (de) * 2002-08-15 2010-04-08 3M Espe Ag Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
EP1600141B1 (en) * 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
AU2006226819A1 (en) * 2005-03-24 2006-09-28 Anacor Pharmaceuticals, Inc. Topical formulations of boronic acid antibiotics and their methods of use
EP1754464A1 (en) * 2005-08-17 2007-02-21 3M Innovative Properties Company Enzyme comprising dental composition
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20100330000A1 (en) * 2007-11-06 2010-12-30 Kristian Hellgren Enzymes for treatment of gingivitis
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
NZ600403A (en) 2009-12-08 2014-01-31 Smith & Nephew Orthopaedics Ag Enzymatic wound debriding compositions with enhanced enzymatic activity
CN106310242B (zh) 2011-04-21 2020-02-28 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
BR112022006369A2 (pt) * 2019-10-03 2022-06-28 S Biomedic Composição inovadora para cuidados com a pele
JP7312993B2 (ja) * 2020-05-25 2023-07-24 静岡県公立大学法人 エラスチン産生促進剤及び皮膚化粧料
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5132M (es) * 1966-01-20 1967-06-05
FR1548652A (es) * 1967-10-27 1968-12-06
EP0133438A1 (en) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Enzyme ointment
US5238843A (en) * 1989-10-27 1993-08-24 Genencor International, Inc. Method for cleaning a surface on which is bound a glycoside-containing substance
DK0425016T3 (da) * 1989-10-27 1996-05-06 Genencor Int Antimikrobiel fremgangsmåde og formulering med anvendelse af type II endoglycosidase og antimikrobielt middel

Also Published As

Publication number Publication date
CA2133085A1 (en) 1993-10-14
KR950700722A (ko) 1995-02-20
DE69325366D1 (de) 1999-07-22
JPH07505383A (ja) 1995-06-15
US5439935A (en) 1995-08-08
BR9306178A (pt) 1998-06-23
AU675426B2 (en) 1997-02-06
GB9207280D0 (en) 1992-05-13
WO1993019731A1 (en) 1993-10-14
EP0633764B1 (en) 1999-06-16
AU3896193A (en) 1993-11-08
GR3031016T3 (en) 1999-12-31
EP0633764A1 (en) 1995-01-18
ATE181231T1 (de) 1999-07-15
DE69325366T2 (de) 1999-11-04
ZA932403B (en) 1994-10-02

Similar Documents

Publication Publication Date Title
ES2132227T3 (es) Procedimiento y composicion para el cuidado de la piel.
ES2119897T3 (es) Procedimiento y composicion para el cuidado de la piel.
ES2095017T3 (es) Composicion cosmetica o farmaceutica que comprende en asociacion una peroxidasa y un agente antioxigeno singulete.
AR009098A1 (es) Una composicion para el acondicionamiento de la piel y metodos cosmeticos que comprenden la aplicacion sobre la piel de dicha composicion
ATE258421T1 (de) Färbemittel zum färben von keratinfasern
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
DE59509751D1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
PT1194115E (pt) Agente contendo idebenona aplicado topicamente, com efeito protector e regenerativo
ES2121793T3 (es) Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
ES2090631T3 (es) Utilizacion de esfingolipidos, en la preparacion de una composicion cosmetica o dermofarmaceutica que protege la piel y los cabellos contra los efectos nocivos de la polucion atmosferica.
ES2042000T3 (es) Dispositivos de inhalacion con riesgo reducido de bloqueo.
BR9714842A (pt) Composições para tingimento capilar
CO4900022A1 (es) Composicion topica y metodo para incrementar la sintesis de la barrera del lipido la barrera de lipido utilizando dicha composicion
ES2087652T3 (es) Composiciones cosmeticas y/o farmaceuticas y metodos para su uso en proteger tejidos del contacto con metales pesados.
ES2092868T3 (es) Utilizacion de derivados de la 4-tiorresorcina en unas composiciones cosmeticas o dermofarmaceuticas de accion despigmentante.
HUT71092A (en) Use of sulphonic acids as anti ageing agent in a cosmetic on dermatological composition
ZA918084B (en) Use of 1,4-di(mono- or poly) hydroxyalkylamino-9,10-anthraquinones for dyeing human keratinous fibres.
NO911233D0 (no) Nye retinoider.
ES2186866T3 (es) Derivados de factores del antibiotico ge2270.
BR9903751A (pt) Composição para uso cosmético e/ou dermatológico, utilização cosmética da composição, utilização da composição e utilização de pelo menos um ácido aminossulfÈnico n-substituìdo
ES2105726T5 (es) Unidad de envasado y procedimiento para su fabricacion.
AR016884A1 (es) Composiciones para el tratamiento del cabello y utilizacion de dicha composicion
ES2173453T3 (es) Nuevos dispositivos destinados a la administracion transdermica de trimegestona.
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c
ES2152541T3 (es) Agente para el cuidado de la piel que contiene tensioactivos no ionicos y biopolimeros cationicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633764

Country of ref document: ES